Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer

Abstract Background Endocrine therapies are still the main strategy for the treatment of oestrogen receptor-positive (ER+) breast cancers (BC), but resistance remains problematic. Cross-talk between ER and PI3K/AKT/mTORC has been associated with ligand-independent transcription of ER. We have previo...

Full description

Bibliographic Details
Main Authors: Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Sophie Chateau-Joubert, Lila Zabaglo, Margaret Hills, Andrew Dodson, Qiong Gao, Stephen R. Johnston, Mitch Dowsett, Sabina C. Cosulich, Elisabetta Maragoni, Lesley-Ann Martin
Format: Article
Language:English
Published: BMC 2019-12-01
Series:Breast Cancer Research
Subjects:
Online Access:https://doi.org/10.1186/s13058-019-1222-0